FDA rejects Nastech's Miacalcin-like nasal spray

07/13/2006 | MSN Money

Nastech Pharmaceutical Co. announced the FDA did not approve its osteoporosis nasal spray, which is similar to Novartis' Miacalcin, due to concerns the combination of the preservative chlorobutanol and calcitonin-salmon could provoke an immune response. The company said it plans to hold discussions with the FDA and may explore other alternatives to gaining regulatory approval.

View Full Article in:

MSN Money

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX